Targeting Angiopoietin-2 in nAMD: Efficacy and Safety Data With Drs. Carl Regillo and Arshad Khanani
Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on January 06, 2023 19:04 ()
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 330305528 series 2794818
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Arshad Khanani discuss the efficacy and safety of therapies targeting Ang-2 in nAMD.